Current Alzheimer Research · 2014 · 51 citations · 66 references
MedicineNeurologyNeuroscienceDementiaNeurochemistryNeuropharmacologyAlzheimer DiseaseCholinergic PharmacologyCholinergic SignalingDementia BiomarkersNeurodegenerative DiseasesNeuroinflammationAche InhibitionAmyloid ToxicityCholinergic Signaling PathwaysNeuroinflammation In Alzheimer DiseaseNeuroinflammatory BiomarkersNeuronal DysfunctionNeurotoxic BiomarkersSymptomatic Pharmacotherapy
Increasing evidence suggests that elevated production and/or reduced clearance of amyloid-β peptide (Aβ) drives the early pathogenesis of Alzheimer's disease (AD). Aβ soluble oligomers trigger a neurotoxic cascade that leads to neuronal dysfunction, neurodegeneration and, ultimately, clinical dementia. Inflammation, both within brain and systemically, together with a deficiency in the neurotransmitter acetylcholine (ACh) that underpinned the development of anticholinesterases for AD symptomatic treatment, are invariable hallmarks of the disease. The inter-relation between Aβ, inflammation and cholinergic signaling is complex, with each feeding back onto the others to drive disease progression. To elucidate these interactions plasma samples and peripheral blood mononuclear cells (PBMCs) were evaluated from healthy controls (HC) and AD patients. Plasma levels of acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and Aβ were significantly elevated in AD vs. HC subjects, and ACh showed a trend towards reduced levels. Aβ challenge of PBMCs induced a greater release of inflammatory cytokines interleukin-1β (IL-1β), monocyte chemotactic protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) from AD vs. HC subjects, with IL-10 being similarly affected. THP-1 monocytic cells, a cell culture counterpart of PBMCs and brain microglial cells, responded similarly to Aβ as well as to phytohaemagglutinin (PHA) challenge, to allow preliminary analysis of the cellular and molecular pathways underpinning Aβ-induced changes in cytokine expression. As amyloid-β precursor protein expression, and hence Aβ, has been reported regulated by particular cytokines and anticholinesterases, the latter were evaluated on Aβ- and PHA-induced chemocytokine expression. Co-incubation with selective AChE/BuChE inhibitors, (-)-phenserine (AChE) and (-)-cymserine analogues (BuChE), mitigated the rise in cytokine levels and suggest that augmentation of the cholinergic anti-inflammatory pathway may prove valuable in AD.
66
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
A new and rapid colorimetric determination of acetylcholinesterase activity
George L. Ellman, K. Diane Courtney, Valentino Andres et al. · Biochemical Pharmacology · 1961 · 26.9K citations
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin
L. V. Borovikova, Svetlana Ivanova, Minghuang Zhang et al. · Nature · 2000 · 4.2K citations
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Hong Wang, Man Yu, Mahendar Ochani et al. · Nature · 2002 · 3.2K citations
Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit
Mauricio Rosas‐Ballina, Peder S. Olofsson, Mahendar Ochani et al. · Science · 2011 · 1.5K citations · Full text